FY26-27 Adult Covid-19 Vaccines

The Centers for Disease Control and Prevention (CDC) is issuing Indefinite Delivery/Indefinite Quantity (ID/IQ) contracts for the procurement of standard commercial adult vaccines, focusing primarily on vaccines for the 2026-2027 season with provisions to acquire vaccines for the 2025-2026 season as needed. These contracts enable the use of Section 317 vaccine purchase funds to secure vaccines at prices more favorable than those typically found in the commercial market. The purpose of this initiative is to support the National Center for Immunization and Respiratory Diseases (NCIRD) immunization awardees, which include all 50 state health departments, several large city programs, and U.S. territories, to enhance adult immunization efforts and improve coverage in populations at higher risk of under vaccination. The contract titled "FY26-27 Adult Covid-19 Vaccines," solicited by the CDC Office of Acquisition Services under the Department of Health and Human Services, is identified with solicitation number 75D30126R73405 and is based in Atlanta, Georgia. No set-aside applies to this procurement, which falls under the NAICS code 325412. The contracts allow awardees to additionally purchase vaccines using their own state and local funds if desired. The CDC aims to partner with healthcare providers in both public and private sectors through Section 317(j) of the Public Health Service Act to enhance immunization practices and vaccine usage. Responses to the solicitation are due by March 17, 2026, and the primary contacts for this procurement are Jariya Taylor and Chad Turner.